advertisement
Abstract #12425 Published in IGR 7-2
Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy
Konstas AG; Boboridis K; Tzetzi D; Kallinderis K; Jenkins JN; Stewart WCArchives of Ophthalmology 2005; 123: 898-902
OBJECTIVE: To evaluate the 24-hour efficacy and safety of the latanoprost-timolol maleate-fixed combination vs latanoprost therapy in patients with primary open-angle glaucoma. METHODS: A prospective, observer-masked, crossover, active-controlled, randomized comparison in which after a 6-week medicine-free period, patients were randomized to either latanoprost-timolol-fixed combination therapy or latanoprost therapy, both dosed once each evening, alone for 8 weeks. Patients were then switched to the opposite treatment for 8 weeks. At the end of the washout and treatment periods, a 24-hour diurnal curve was performed. RESULTS: The baseline untreated mean ± SD diurnal curve in 37 patients who completed the study was 24.2 ± 2.0 mmHg. The mean diurnal curve was 19.2 ± 2.6 mmHg for those who received latanoprost therapy alone and 16.7 ± 2.1 mmHg for those who received the fixed combination therapy (P < .001). The fixed combination therapy also provided a lower absolute intraocular pressure level (1.5-2.9 mmHg, P < .001) and a greater intraocular pressure reduction from the untreated baseline (P < .001). Stinging was statistically lower with latanoprost therapy alone (P = .04), but itching was statistically increased compared with the fixed combination therapy (P = .04). CONCLUSION: The result of this study suggests that the latanoprost-timolol-fixed combination compared with latanoprost therapy alone provides improved intraocular pressure reduction over the 24-hour diurnal curve and for each individual time point in patients with primary open-angle glaucoma.
Dr. A.G. Konstas, Glaucoma Unit, University Department of Ophthalmology, Australasian Hellenic Educational Progressive Association Hospital, Thessaloniki, Greece
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
